Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

University Hospital, Montpellier65 enrolled

Overview

Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lymphoma, B-Cell

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: \- patient with a Diagnosis of LBDGC-SNC Exclusion criteria: * immunocompromised patients * patients with a history of previous or associated low-grade lymphoma * patients with a history of systemic LBDGC with secondary localization to the SNC

Locations (1)

Uh Montpellier

Montpellier, France

Outcomes

Primary Outcomes

TIM-3 and Gal-9 immunohistochemical expression

TIM-3 and Gal-9 immunohistochemical expression by tumor and microenvironment cells

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.